EA201891420A1 - Антитела к миостатину, полипептиды, содержащие варианты fc-областей, и способы их применения - Google Patents
Антитела к миостатину, полипептиды, содержащие варианты fc-областей, и способы их примененияInfo
- Publication number
- EA201891420A1 EA201891420A1 EA201891420A EA201891420A EA201891420A1 EA 201891420 A1 EA201891420 A1 EA 201891420A1 EA 201891420 A EA201891420 A EA 201891420A EA 201891420 A EA201891420 A EA 201891420A EA 201891420 A1 EA201891420 A1 EA 201891420A1
- Authority
- EA
- Eurasian Patent Office
- Prior art keywords
- myostatin
- methods
- polypeptides
- antibodies
- regions
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/06—Anabolic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/524—CH2 domain
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/526—CH3 domain
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/53—Hinge
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/567—Framework region [FR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/71—Decreased effector function due to an Fc-modification
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Neurology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Obesity (AREA)
- Child & Adolescent Psychology (AREA)
- Endocrinology (AREA)
- Hematology (AREA)
- Pain & Pain Management (AREA)
- Diabetes (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2015247070 | 2015-12-18 | ||
| PCT/JP2016/087487 WO2017104783A1 (en) | 2015-12-18 | 2016-12-16 | Anti-myostatin antibodies, polypeptides containing variant fc regions, and methods of use |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| EA201891420A1 true EA201891420A1 (ru) | 2019-02-28 |
Family
ID=59011957
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EA201891420A EA201891420A1 (ru) | 2015-12-18 | 2016-12-16 | Антитела к миостатину, полипептиды, содержащие варианты fc-областей, и способы их применения |
Country Status (16)
| Country | Link |
|---|---|
| EP (1) | EP3390443A4 (zh) |
| JP (4) | JP6142069B1 (zh) |
| KR (4) | KR20240058997A (zh) |
| CN (2) | CN108473562B (zh) |
| AR (1) | AR107078A1 (zh) |
| AU (1) | AU2016372934B2 (zh) |
| BR (1) | BR112018011073A2 (zh) |
| CA (1) | CA3002422C (zh) |
| EA (1) | EA201891420A1 (zh) |
| HK (1) | HK1254755A1 (zh) |
| MX (1) | MX2018007145A (zh) |
| MY (1) | MY189425A (zh) |
| PH (1) | PH12018501280A1 (zh) |
| SG (2) | SG10201707267RA (zh) |
| TW (3) | TW202231662A (zh) |
| WO (1) | WO2017104783A1 (zh) |
Families Citing this family (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP4001409A1 (en) | 2006-03-31 | 2022-05-25 | Chugai Seiyaku Kabushiki Kaisha | Methods for controlling blood pharmacokinetics of antibodies |
| DK2202245T3 (en) | 2007-09-26 | 2016-11-21 | Chugai Pharmaceutical Co Ltd | A method of modifying an antibody isoelectric point VIA amino acid substitution in CDR |
| EP3521311A1 (en) | 2008-04-11 | 2019-08-07 | Chugai Seiyaku Kabushiki Kaisha | Antigen-binding molecule capable of binding to two or more antigen molecules repeatedly |
| CA2819356C (en) | 2010-11-30 | 2023-01-24 | Chugai Seiyaku Kabushiki Kaisha | Antigen-binding molecule capable of binding to plurality of antigen molecules repeatedly |
| AU2013268418B2 (en) | 2012-05-30 | 2017-12-07 | Chugai Seiyaku Kabushiki Kaisha | Target-tissue-specific antigen-binding molecule |
| KR20230110836A (ko) | 2012-08-24 | 2023-07-25 | 추가이 세이야쿠 가부시키가이샤 | ＦｃγＲＩＩｂ 특이적 Ｆｃ영역 개변체 |
| US11236168B2 (en) | 2012-08-24 | 2022-02-01 | Chugai Seiyaku Kabushiki Kaisha | Mouse FcγammaRII-specific Fc antibody |
| EP2982689B1 (en) | 2013-04-02 | 2020-08-26 | Chugai Seiyaku Kabushiki Kaisha | Fc region variant |
| WO2015083764A1 (ja) | 2013-12-04 | 2015-06-11 | 中外製薬株式会社 | 化合物の濃度に応じて抗原結合能の変化する抗原結合分子及びそのライブラリ |
| NZ730607A (en) | 2014-12-19 | 2022-07-01 | Chugai Pharmaceutical Co Ltd | Anti-myostatin antibodies, polypeptides containing variant fc regions, and methods of use |
| EA201791754A1 (ru) | 2015-02-05 | 2019-01-31 | Чугаи Сейяку Кабусики Кайся | АНТИТЕЛА, СОДЕРЖАЩИЕ ЗАВИСЯЩИЙ ОТ КОНЦЕНТРАЦИИ ИОНОВ АНТИГЕНСВЯЗЫВАЮЩИЙ ДОМЕН, ВАРИАНТЫ Fc-ОБЛАСТИ, IL-8-СВЯЗЫВАЮЩИЕ АНТИТЕЛА И ИХ ПРИМЕНЕНИЯ |
| SG10201707267RA (en) * | 2015-12-18 | 2017-10-30 | Chugai Pharmaceutical Co Ltd | Anti-myostatin antibodies, polypeptides containing variant fc regions, and methods of use |
| JP7141336B2 (ja) | 2015-12-25 | 2022-09-22 | 中外製薬株式会社 | 抗ミオスタチン抗体および使用方法 |
| KR102306744B1 (ko) * | 2016-06-17 | 2021-09-28 | 추가이 세이야쿠 가부시키가이샤 | 항-마이오스타틴 항체 및 사용 방법 |
| CN109689099B (zh) | 2016-08-05 | 2023-02-28 | 中外制药株式会社 | 用于预防或治疗il-8相关疾病的组合物 |
| MX2019010028A (es) | 2017-02-28 | 2019-10-14 | Seattle Genetics Inc | Anticuerpos con cisteina mutada por conjugacion. |
| AU2019318031A1 (en) | 2018-08-10 | 2021-02-25 | Chugai Seiyaku Kabushiki Kaisha | Anti-CD137 antigen-binding molecule and utilization thereof |
| KR20210149779A (ko) | 2019-04-10 | 2021-12-09 | 추가이 세이야쿠 가부시키가이샤 | Fc 영역 개변 항체의 정제 방법 |
| KR20220093103A (ko) * | 2019-09-13 | 2022-07-05 | 어드메어 테라퓨틱스 소사이어티 | 항종양용해 바이러스 항원 항체 및 이의 사용 방법 |
| RU2750267C1 (ru) * | 2020-02-07 | 2021-06-25 | Общество с ограниченной ответственностью «НАУЧНО-ПРОИЗВОДСТВЕННОЕ ОБЪЕДИНЕНИЕ ИН-ВЕТ» | Рекомбинантный ростовой дифференцировочный фактор роста 11 (GDF11), способ его получения, инъекционный препарат для повышения мышечной массы млекопитающих животных и птицы, а также способ использования препарата |
| TW202144395A (zh) | 2020-02-12 | 2021-12-01 | 日商中外製藥股份有限公司 | 用於癌症之治療的抗cd137抗原結合分子 |
| WO2023057404A1 (en) | 2021-10-06 | 2023-04-13 | F. Hoffmann-La Roche Ag | Novel combined administration |
| WO2023187022A1 (en) | 2022-04-01 | 2023-10-05 | F. Hoffmann-La Roche Ag | New treatment for facioscapulohumeral muscular dystrophy (fshd) |
| KR20230156844A (ko) | 2022-05-02 | 2023-11-14 | 노보 노르디스크 에이/에스 | 고농도 조성물 및 피하 투여에 적합한 신규한 항-angptl3 항체 |
| WO2024081932A1 (en) | 2022-10-14 | 2024-04-18 | Genentech, Inc. | Methods for treating spinal muscular atrophy |
| CN116990528B (zh) * | 2023-09-27 | 2024-02-06 | 成都华西海圻医药科技有限公司 | 一种基于Gyrolab平台快速测定抗CD40单抗的分析方法 |
Family Cites Families (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7320789B2 (en) * | 2001-09-26 | 2008-01-22 | Wyeth | Antibody inhibitors of GDF-8 and uses thereof |
| US7261893B2 (en) * | 2002-10-22 | 2007-08-28 | Wyeth | Neutralizing antibodies against GDF-8 and uses therefor |
| ES2629397T3 (es) * | 2004-09-24 | 2017-08-09 | Amgen Inc. | Moléculas de Fc modificadas |
| US8008453B2 (en) * | 2005-08-12 | 2011-08-30 | Amgen Inc. | Modified Fc molecules |
| JP5058261B2 (ja) * | 2006-09-05 | 2012-10-24 | イーライ リリー アンド カンパニー | 抗ミオスタチン抗体 |
| PE20091163A1 (es) * | 2007-11-01 | 2009-08-09 | Wyeth Corp | Anticuerpos para gdf8 |
| EP3521311A1 (en) | 2008-04-11 | 2019-08-07 | Chugai Seiyaku Kabushiki Kaisha | Antigen-binding molecule capable of binding to two or more antigen molecules repeatedly |
| AR074777A1 (es) * | 2008-12-19 | 2011-02-09 | Glaxo Group Ltd | Proteinas de union a antigeno |
| BR112012022917A2 (pt) * | 2010-03-11 | 2017-01-10 | Pfizer | anticorpos com ligação a antígeno dependente de ph |
| UY33421A (es) * | 2010-06-03 | 2011-12-30 | Glaxo Wellcome House | Proteinas de union al antígeno humanizados |
| RS57414B1 (sr) * | 2012-03-16 | 2018-09-28 | Regeneron Pharma | Antitela sa lakim lancem konstruisanim sa histidinom i genetički modifikovani glodari za generisanje istih |
| TWI619729B (zh) * | 2012-04-02 | 2018-04-01 | 再生元醫藥公司 | 抗－ｈｌａ－ｂ*２７抗體及其用途 |
| KR20150041662A (ko) * | 2012-08-13 | 2015-04-16 | 리제너론 파아마슈티컬스, 인크. | Ｐｈ-의존적 결합 특성을 갖는 항-ｐｃｓｋ9 항체 |
| KR20230110836A (ko) * | 2012-08-24 | 2023-07-25 | 추가이 세이야쿠 가부시키가이샤 | ＦｃγＲＩＩｂ 특이적 Ｆｃ영역 개변체 |
| CA2911514A1 (en) * | 2013-05-06 | 2014-11-13 | Scholar Rock, Inc. | Compositions and methods for growth factor modulation |
| CN105960414A (zh) * | 2013-08-14 | 2016-09-21 | 诺华股份有限公司 | 治疗散发性包涵体肌炎的方法 |
| CA3005158A1 (en) * | 2014-11-06 | 2016-05-12 | Scholar Rock, Inc. | Anti-pro/latent-myostatin antibodies and uses thereof |
| WO2016073906A2 (en) * | 2014-11-06 | 2016-05-12 | Scholar Rock, Inc. | Transforming growth factor-related immunoassays |
| NZ730607A (en) * | 2014-12-19 | 2022-07-01 | Chugai Pharmaceutical Co Ltd | Anti-myostatin antibodies, polypeptides containing variant fc regions, and methods of use |
| SG10201707267RA (en) * | 2015-12-18 | 2017-10-30 | Chugai Pharmaceutical Co Ltd | Anti-myostatin antibodies, polypeptides containing variant fc regions, and methods of use |
-
2016
- 2016-12-16 SG SG10201707267RA patent/SG10201707267RA/en unknown
- 2016-12-16 WO PCT/JP2016/087487 patent/WO2017104783A1/en active Application Filing
- 2016-12-16 KR KR1020247013912A patent/KR20240058997A/ko active Search and Examination
- 2016-12-16 MY MYPI2018702306A patent/MY189425A/en unknown
- 2016-12-16 KR KR1020187001235A patent/KR102501335B1/ko active IP Right Grant
- 2016-12-16 CA CA3002422A patent/CA3002422C/en active Active
- 2016-12-16 BR BR112018011073A patent/BR112018011073A2/pt active Search and Examination
- 2016-12-16 SG SG11201610812WA patent/SG11201610812WA/en unknown
- 2016-12-16 EP EP16875757.3A patent/EP3390443A4/en active Pending
- 2016-12-16 TW TW110149330A patent/TW202231662A/zh unknown
- 2016-12-16 MX MX2018007145A patent/MX2018007145A/es unknown
- 2016-12-16 EA EA201891420A patent/EA201891420A1/ru unknown
- 2016-12-16 TW TW106129765A patent/TWI749057B/zh active
- 2016-12-16 TW TW105141729A patent/TWI605057B/zh active
- 2016-12-16 CN CN201680072782.7A patent/CN108473562B/zh active Active
- 2016-12-16 CN CN202210678733.5A patent/CN115028721A/zh active Pending
- 2016-12-16 JP JP2016244254A patent/JP6142069B1/ja active Active
- 2016-12-16 KR KR1020177003241A patent/KR101820637B1/ko active IP Right Grant
- 2016-12-16 AR ARP160103887A patent/AR107078A1/es unknown
- 2016-12-16 AU AU2016372934A patent/AU2016372934B2/en active Active
- 2016-12-16 KR KR1020237005092A patent/KR20230027321A/ko not_active IP Right Cessation
-
2017
- 2017-05-08 JP JP2017092151A patent/JP7053164B2/ja active Active
-
2018
- 2018-06-14 PH PH12018501280A patent/PH12018501280A1/en unknown
- 2018-10-29 HK HK18113798.7A patent/HK1254755A1/zh unknown
-
2022
- 2022-03-31 JP JP2022058710A patent/JP2022097485A/ja active Pending
-
2023
- 2023-11-29 JP JP2023201204A patent/JP2024023427A/ja active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EA201891420A1 (ru) | Антитела к миостатину, полипептиды, содержащие варианты fc-областей, и способы их применения | |
| EA201791253A1 (ru) | Антитела к миостатину, полипептиды, содержащие варианты fc-областей, и способы их применения | |
| EA201990017A1 (ru) | Антитела к миостатину и способы их применения | |
| MX2023008559A (es) | Proteínas de fusión fc heterodiméricas il15/il15ra. | |
| MX2022001222A (es) | Anticuerpos anti proteina inmunoglobulina de linfocitos t y dominio de mucina 3 (tim-3) y metodos para usarlos. | |
| EA201991383A1 (ru) | Антитела против ctla-4 и способы их применения | |
| BR112017025564A2 (pt) | anticorpos anti-ctla-4 e métodos de uso dos mesmos | |
| EA201791029A1 (ru) | Антитела против интерлейкина-33 и их применение | |
| EA201591515A1 (ru) | Полипептиды il-22, химерные белки il-22 fc и их применение | |
| EA201790505A1 (ru) | Соединение, нацеленое на ил-23а и фно-альфа, и его применение | |
| CY1122214T1 (el) | Αντισωματα ειδικα για ton fcrn | |
| EA201792080A1 (ru) | Гуманизированные анти-c1s антитела и способы их применения | |
| EA201792466A1 (ru) | АНТИТЕЛА ПРОТИВ FcRn | |
| TH1701003441A (th) | แอนติ-ไมโอสแตตินแอนติบอดี, โพลีเปปไทด์ที่ประกอบด้วยบริเวณแวเรียน Fc และวิธีการของการใช้ | |
| EA202090582A2 (ru) | ПОЛИПЕПТИДЫ IL-22, ХИМЕРНЫЕ БЕЛКИ IL-22 Fc И ИХ ПРИМЕНЕНИЕ |